Genetically Engineered Murine Models of RCC William Y. Kim, M.D.

Immune Characteriza/on of Basal- like Bladder Cancer

Immune Characteriza/on of - like Bladder Cancer William Y. Kim, M.D. Departments of Medicine and Gene2cs Lineberger Comprehensive Cancer Center University of North Carolina Chapel Hill, NC 5 year survival

Molecular Classification of Triple-Negative Breast Cancer (TNBC) Aleix Prat, MD

Molecular Classification of Triple-Negative Breast Cancer (TNBC) Emerging genomic and clinical data Aleix Prat, MD Postdoctoral Research Associate at Perou Lab Lineberger Comprehensive Cancer Center University

The Cancer Genome Atlas Pan-cancer analysis Katherine A. Hoadley

The Cancer Genome Atlas Pan-cancer analysis Katherine A. Hoadley Department of Genetics Lineberger Comprehensive Cancer Center The University of North Carolina at Chapel Hill What is TCGA? The Cancer Genome

RCC with Sarcomatoid Dedifferentiation: New Insights. Jose A. Karam, MD, FACS Assistant Professor Department of Urology November 6, 2015

RCC with Sarcomatoid Dedifferentiation: New Insights Jose A. Karam, MD, FACS Assistant Professor Department of Urology November 6, 2015 Farrow GM. Cancer. 1968 Epidemiology of srcc ~5% of all renal tumors

Molecular Pathology of Renal Cell Carcinoma: An Update

Molecular Pathology of Renal Cell Carcinoma: An Update George J. Netto, M.D. Professor and Chair of Pathology Robert And Ruth Endowed Chair in Pathology University of Alabama at Birmingham Enterprise Interest

Fraction of genes mutated

Fraction of genes copy number altered 0.0 0.2 0.4 0.6 0.8 1.0 SNU349 CCLP Kidney Kidney TCGA KIRC 0.00 0.05 0.10 0.15 0.20 Fraction of genes Supplementary Figure 1. Mutational burden and copy number alterations

Case Based Learning Program

Case Based Learning Program The Department of Urology Glickman Urological & Kidney Institute Cleveland Clinic Case Number 5 CBULP 2010 001 Case Based Urology Learning Program Editor: Associate Editor:

The Met Pathway as a Target in RCC

The Met Pathway as a Target in RCC Harriet Kluger, M.D. Associate Professor Yale Cancer Center Disclosures pertinent to this presentation - none c-met Pathway (Biocarta) Rationale for c-met targeting in

Kinome Profiling: The Potential in ER-Negative Patients. Charles M. Perou, Ph.D. Departments of Genetics and Pathology

Kinome Profiling: The Potential in ER-Negative Patients Charles M. Perou, Ph.D. Departments of Genetics and Pathology Lineberger Comprehensive Cancer Center University of North Carolina Chapel Hill, North

CONTRACTING ORGANIZATION: Vanderbilt University Medical Center Nashville, TN

AD Award Number: W81XWH-04-1-0867 TITLE: A Myc-Driven in Vivo Model of Human Prostate Cancer PRINCIPAL INVESTIGATOR: Simon W. Hayward, Ph.D. CONTRACTING ORGANIZATION: Vanderbilt University Medical Center

RNA SEQUENCING AND DATA ANALYSIS

RNA SEQUENCING AND DATA ANALYSIS Download slides and package http://odin.mdacc.tmc.edu/~rverhaak/package.zip http://odin.mdacc.tmc.edu/~rverhaak/rna-seqlecture.zip Overview Introduction into the topic

Computer Science, Biology, and Biomedical Informatics (CoSBBI) Outline. Molecular Biology of Cancer AND. Goals/Expectations. David Boone 7/1/2015

Goals/Expectations Computer Science, Biology, and Biomedical (CoSBBI) We want to excite you about the world of computer science, biology, and biomedical informatics. Experience what it is like to be a

Dynamic reprogramming of DNA methylation in SETD2- deregulated renal cell carcinoma

/, Vol. 7, No. 2 Dynamic reprogramming of DNA methylation in SETD2- deregulated renal cell carcinoma Rochelle L. Tiedemann 1, Ryan A. Hlady 2, Paul D. Hanavan 3, Douglas F. Lake 3, Raoul Tibes 4,5, Jeong-Heon

TITLE: Effects of Tobacco Smoke (TS) on growth of clear cell renal cell carcinoma (ccrcc)

AD Award Number: W81XWH-14-1-0347 TITLE: Effects of Tobacco Smoke (TS) on growth of clear cell renal cell carcinoma (ccrcc) PRINCIPAL INVESTIGATOR: Maria F. Czyzyk-Krzeska CONTRACTING ORGANIZATION: University

VHL Syndrome and Hemangioblastoma Management

VHL Syndrome and Hemangioblastoma Management Eric Jonasch Professor of Medicine UT MD Anderson Cancer Center Fourteenth International Kidney Cancer Symposium Miami, Florida, USA November 6-7, 2015 www.kidneycancersymposium.com

Enterprise Interest Nothing to declare

Enterprise Interest Nothing to declare Biopsy diagnosis of renal tumors. Current applications Ondřej Hes Department of Pathology Charles University and University Hospital Plzeň Czech Republic Dealing

Various hereditary, acquired and neoplastic conditions can lead to cyst formation in the kidney.

Dr. Fatima AlAl-Hashimi Hashimi,, MD, FRCPath Salmaniya Medical Complex, Bahrain Various hereditary, acquired and neoplastic conditions can lead to cyst formation in the kidney. The most frequently encountered

10/15/2012. Biologic Subtypes of TNBC. Topics. Topics. Histopathology Molecular pathology Clinical relevance

Biologic Subtypes of TNBC Andrea L. Richardson M.D. Ph.D. Brigham and Women s Hospital Dana-Farber Cancer Institute Harvard Medical School Boston, MA Topics Histopathology Molecular pathology Clinical

ncounter Assay Automated Process Capture & Reporter Probes Bind reporter to surface Remove excess reporters Hybridize CodeSet to RNA

ncounter Assay Automated Process Hybridize CodeSet to RNA Remove excess reporters Bind reporter to surface Immobilize and align reporter Image surface Count codes mrna Capture & Reporter Probes slides

Updates in Urologic Pathology WHO Made Those Changes?! Peyman Tavassoli Pathology Department BC Cancer Agency

Updates in Urologic Pathology WHO Made Those Changes?! Peyman Tavassoli Pathology Department BC Cancer Agency World Health Organization Available in Feb 2016 Frame work for reporting Major contributing

Bmi-1 regulates stem cell-like properties of gastric cancer cells via modulating mirnas

Wang et al. Journal of Hematology & Oncology (2016) 9:90 DOI 10.1186/s13045-016-0323-9 RESEARCH Bmi-1 regulates stem cell-like properties of gastric cancer cells via modulating mirnas Open Access Xiaofeng

mirna Dr. S Hosseini-Asl

mirna Dr. S Hosseini-Asl 1 2 MicroRNAs (mirnas) are small noncoding RNAs which enhance the cleavage or translational repression of specific mrna with recognition site(s) in the 3 - untranslated region

Renal Cell Carcinoma: Research And Treatments

Renal Cell Carcinoma: Research And Treatments Renal Cell Carcinoma - Medscape - therapies for treatment of advanced renal cell carcinoma? for Research and Treatment of Cancer of renal cell carcinoma. Renal

ROLE OF TGF-BETA SIGNALING IN PIK3CA-

ROLE OF TGF-BETA SIGNALING IN - DRIVEN HEAD AND NECK CANCER INVASION AND METASTASIS 1,2 Sophia Bornstein, 3 Jingping Shen, 3 Jacob Minor, 3 Frank Hall, 3 Fang Zhang, 4 Sherif Said, 4 Xiao-Jing Wang, 1

Rath, N., and Olson, M. (2016) Regulation of pancreatic cancer aggressiveness by stromal stiffening. Nature Medicine, 22(5), pp. 462-463. There may be differences between this version and the published

Circulating tumor cells/dna/etc for Radiation Oncologists

Circulating tumor cells/dna/etc for Radiation Oncologists Andrew Z. Wang, M.D. Associate Professor Director of Clinical and Translational Research Department of Radiation Oncology Carolina Center for Cancer

ncounter Assay Automated Process Immobilize and align reporter for image collecting and barcode counting ncounter Prep Station

ncounter Assay ncounter Prep Station Automated Process Hybridize Reporter to RNA Remove excess reporters Bind reporter to surface Immobilize and align reporter Image surface Count codes Immobilize and

UNC Board of Trustees March 25, 2010

UNC Board of Trustees March 25, 2010 UNC Lineberger: The Public Comprehensive Cancer Center Basic research: Molecular discovery Clinical Research: Diagnostics & Therapeutics Clinical Care: Patient-centered

Relationship between SPOP mutation and breast cancer in Chinese population

Relationship between SPOP mutation and breast cancer in Chinese population M.A. Khan 1 *, L. Zhu 1 *, M. Tania 1, X.L. Xiao 2 and J.J. Fu 1 1 Key Laboratory of Epigenetics and Oncology, The Research Center

Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker

Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction

Cancer Genetics. What is Cancer? Cancer Classification. Medical Genetics. Uncontrolled growth of cells. Not all tumors are cancerous

Session8 Medical Genetics Cancer Genetics J avad Jamshidi F a s a U n i v e r s i t y o f M e d i c a l S c i e n c e s, N o v e m b e r 2 0 1 7 What is Cancer? Uncontrolled growth of cells Not all tumors

Breeding scheme, transgenes, histological analysis and site distribution of SB-mutagenized osteosarcoma.

Supplementary Figure 1 Breeding scheme, transgenes, histological analysis and site distribution of SB-mutagenized osteosarcoma. (a) Breeding scheme. R26-LSL-SB11 homozygous mice were bred to Trp53 LSL-R270H/+

Renal Cell Carcinoma: Genetics & Imaging Srinivasa R Prasad University of Texas San Antonio

Renal Cell Carcinoma: Genetics & Imaging Srinivasa R Prasad University of Texas HSC @ San Antonio No financial disclosures Acknowledgements Dr. Peter Choyke, NIH My Gurus @ MIR, MGH 2004 WHO Taxonomy of

Case Based Urology Learning Program

Case Based Urology Learning Program Resident s Corner: UROLOGY Case Number 18 CBULP 2011 041 Case Based Urology Learning Program Editor: Associate Editors: Manager: Case Contributors: Steven C. Campbell,

Renal tumors of adults

Renal tumors of adults Urinary Tract Tumors 2%-3% of all cancers in adults. The most common malignant tumor of the kidney is renal cell carcinoma. Tumors of the lower urinary tract are twice as common

Genome Editing Research for Translational Toxicology Solutions

Genome Editing Research for Translational Toxicology Solutions REBECCA FRY, PH.D. Carol Remmer Angle Distinguished Professor and Associate Chair Director, UNC Superfund Research Program Director, Graduate

Pancreatic Adenocarcinoma: What`s hot

Pancreatic Adenocarcinoma: What`s hot Eva Karamitopoulou-Diamantis Institute of Pathology University of Bern 11.09.2018, 30th ECP, Bilbao Pancreatic Cancer and the Microbiome The Pancreatic Cancer Microbiome

Androgen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target?

Androgen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target? New Frontiers in Urologic Oncology Juan Chipollini, MD Clinical Fellow Department of Genitourinary Oncology Moffitt Cancer

Future outlooks in NET: The pathologists point of view. Aurel Perren, Institute of Pathology University of Bern

Future outlooks in NET: The pathologists point of view Aurel Perren, Institute of Pathology University of Bern ESMO Preceptorship on GI neuroendocrine tumors (NETs) Leuven, November 2014 Near Future >

Pharmacogenetics of the VEGF pathway. Federico Innocenti, MD, PhD University of North Carolina Chapel Hill, NC, USA

Pharmacogenetics of the VEGF pathway Federico Innocenti, MD, PhD University of North Carolina Chapel Hill, NC, USA Angiogenesis o Angiogenesis an important process for tumor biology o Tumor growth and

10/11/2018. Clinical and Surgical Management of VHL-Related Cysts and Cystic RCC. Outline. VHL Renal Manifestations. VHL Renal Manifestations

Outline Clinical and Surgical Management of VHL-Related Cysts and Cystic RCC Mark W. Ball, MD Assistant Research Physician Attending Surgeon Urologic Oncology Branch, National Cancer Institute Prevalence

Molecular mechanisms of the T cellinflamed tumor microenvironment: Implications for cancer immunotherapy

Molecular mechanisms of the T cellinflamed tumor microenvironment: Implications for cancer immunotherapy Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader,

The role of the Von Hippel-Lindau tumor suppressor protein in clear cell renal carcinoma

The role of the Von Hippel-Lindau tumor suppressor protein in clear cell renal carcinoma Sharif Rahmy, Alyson MacInnes Abstract Up to 88% of patients who suffer from clear cell renal carcinoma (ccrcc)

THE BIOLOGY OF CANCER. Dr Jim Edwards Medical Oncologist Canterbury District Health Board

THE BIOLOGY OF CANCER Dr Jim Edwards Medical Oncologist Canterbury District Health Board OVERVIEW Historical perspectives on Cancer Biology? Important principles of Cancer Biology Why is understanding

PAX8-PPARγ Fusion Protein in thyroid carcinoma

Sidney H. Ingbar Lecture, ATA 10/17/2013: PAX8-PPARγ Fusion Protein in thyroid carcinoma Ronald J. Koenig, MD, PhD Division of Metabolism, Endocrinology & Diabetes University of Michigan Learning Objectives

EPIGENETIC RE-EXPRESSION OF HIF-2α SUPPRESSES SOFT TISSUE SARCOMA GROWTH

EPIGENETIC RE-EXPRESSION OF HIF-2α SUPPRESSES SOFT TISSUE SARCOMA GROWTH Supplementary Figure 1. Supplementary Figure 1. Characterization of KP and KPH2 autochthonous UPS tumors. a) Genotyping of KPH2

Comprehensive Molecular Characterization of Urachal Adenocarcinoma Reveals Commonalities With Colorectal Cancer, Including a Hypermutable Phenotype

original report Comprehensive Molecular Characterization of Urachal Adenocarcinoma Reveals Commonalities With Colorectal Cancer, Including a Hypermutable Phenotype Jordan Kardos Sara E. Wobker Michael

number Done by Corrected by Doctor Maha Shomaf

number 19 Done by Waseem Abo-Obeida Corrected by Abdullah Zreiqat Doctor Maha Shomaf Carcinogenesis: the molecular basis of cancer. Non-lethal genetic damage lies at the heart of carcinogenesis and leads

TAT meeting Paris Can the tumor genome help us to better select patients for antiangiogenic therapy?

TAT meeting Paris 2011 Can the tumor genome help us to better select patients for antiangiogenic therapy? Emile E Voest Department of Medical Oncology UMC Utrecht Cancer Center Modest succes of bevacizumab

DNA methylation in Uropathology

DNA methylation in Uropathology Clinical significance Rui Henrique, MD, PhD Director, Department of Pathology Difrector, Department of Education Senior Researcher, Cancer Biology and Epigenetics Group

Oncogenes and Tumor Suppressors MCB 5068 November 12, 2013 Jason Weber

Oncogenes and Tumor Suppressors MCB 5068 November 12, 2013 Jason Weber jweber@dom.wustl.edu Oncogenes & Cancer DNA Tumor Viruses Simian Virus 40 p300 prb p53 Large T Antigen Human Adenovirus p300 E1A

PT2385: HIF 2α Antagonist for the Treatment of. Peloton Therapeutics, Inc. 5/4/ th International VHL Medical Symposium April 8, 2016

5/4/216 : Antagonist for the Treatment of VHL Mutant ccrcc 12th International VHL Medical Symposium Eli Wallace, Ph.D. Vice President of Chemistry Disclosure Information Eli Wallace I have the following

Stergios Moschos, MD

Stergios Moschos, MD Clinical Associate Professor of Medicine Department of Medicine Division of Hematology/Oncology University of North Carolina at Chapel Hill Solid Tumor with one of the Highest Mutation

Cancer. The fundamental defect is. unregulated cell division. Properties of Cancerous Cells. Causes of Cancer. Altered growth and proliferation

Cancer The fundamental defect is unregulated cell division. Properties of Cancerous Cells Altered growth and proliferation Loss of growth factor dependence Loss of contact inhibition Immortalization Alterated

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

AWARD NUMBER: W81XWH-13-1-0184 TITLE: In Vivo Tagging of Lung Epithelial Cells To Define the Early Steps of Tumor Cell Dissemination PRINCIPAL INVESTIGATOR: Hasmeena Kathuria, MD CONTRACTING ORGANIZATION:

Tumor Purity and Immune Cell Infiltration as a Prognostic Risk Predictor for Clear Cell Renal Cell Carcinoma (ccrcc)

Tumor Purity and Immune Cell Infiltration as a Prognostic Risk Predictor for Clear Cell Renal Cell Carcinoma (ccrcc) Andrew G. Winer, Yasin Senbabaoglu, Samuel D Kaffenberger, Jonathan A. Coleman, Paul

Microarray Analysis and Liver Diseases

Microarray Analysis and Liver Diseases Snorri S. Thorgeirsson M.D., Ph.D. Laboratory of Experimental Carcinogenesis Center for Cancer Research, NCI, NIH Application of Microarrays to Cancer Research Identifying

Pancreatic intraepithelial

Pancreatic intraepithelial neoplasia (PanIN) Markéta Hermanová St. Anne s University Hospital Brno Faculty of Medicine, Masaryk University Precursor lesions of invasive pancreatic cancer Pancreatic intraepithelial

VIII Curso Internacional del PIRRECV. Some molecular mechanisms of cancer

VIII Curso Internacional del PIRRECV Some molecular mechanisms of cancer Laboratorio de Comunicaciones Celulares, Centro FONDAP Estudios Moleculares de la Celula (CEMC), ICBM, Facultad de Medicina, Universidad

Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN

UNC-6/Netrin mediates dendritic self-avoidance Cody J. Smith 1, Joseph D. Watson 1,4,5, Miri K. VanHoven 2, Daniel A. Colón-Ramos 3 and David M. Miller III 1,4,6 1 Department of Cell and Developmental

RCC in Adolescents and Young Adults (AYAs): Diagnosis and Management

RCC in Adolescents and Young Adults (AYAs): Diagnosis and Management Nicholas G. Cost, M.D. Assistant Professor, Department of Surgery, Division of Urology University of Colorado Cancer Center Fifteenth

Colon Cancer and Hereditary Cancer Syndromes

Colon Cancer and Hereditary Cancer Syndromes Gisela Keller Institute of Pathology Technische Universität München gisela.keller@lrz.tum.de Colon Cancer and Hereditary Cancer Syndromes epidemiology models

A class of genes that normally suppress cell proliferation. p53 and Rb..ect. suppressor gene products can release cells. hyperproliferation.

Tumor Suppressor Genes A class of genes that normally suppress cell proliferation. p53 and Rb..ect Mutations that inactivate the tumor suppressor gene products can release cells from growth suppression

TITLE: Central Tolerance Blockade to Augment Checkpoint Immunotherapy in Melanoma

AWARD NUMBER: W81XWH-15-1-0411 TITLE: Central Tolerance Blockade to Augment Checkpoint Immunotherapy in Melanoma PRINCIPAL INVESTIGATOR: Maureen Su CONTRACTING ORGANIZATION: The University of North Carolina

ACCME/Disclosures. M31078/07 Ondřej Hes 4/13/2016

M31078/07 Ondřej Hes Department of Pathology Charles University and University Hospital Plzeň Bioptická laboratoř Plzeň Czech Republic ACCME/Disclosures The USCAP requires that anyone in a position to

Cancer. Death Rates for the Main Causes of Death in the U.S. Leading Sites of New Cases & Deaths (2015 estimates in the U.S.)

11/25/17 Learning Goals for This Lecture Cancer - To recognize that cancer largely is a preventable disease. - To recognize that cancer is a disease of our own genes. Weimin Zhong, Ph.D. weimin.zhong@yale.edu

Contents 1 The Windows of Susceptibility to Breast Cancer 2 The So Called Pre-Neoplastic Lesions and Carcinoma In Situ

Contents 1 The Windows of Susceptibility to Breast Cancer... 1 1.1 Introduction... 1 1.2 Risk Factor and Etiological Agents... 2 1.3 The Concept of the Windows of Susceptibility to Carcinogenesis... 5

Predictive Biomarkers for Pembrolizumab. Eric H. Rubin, M.D.

Predictive Biomarkers for Pembrolizumab Eric H. Rubin, M.D. PD-1 and PD-L1/L2 Pathway PD-1 is an immune checkpoint receptor Binding of PD-1 by its ligands PD-L1 or PD-L2 leads to downregulation of T-cell

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, MD

AD Award Number: W81XWH-11-1-0126 TITLE: Chemical strategy to translate genetic/epigenetic mechanisms to breast cancer therapeutics PRINCIPAL INVESTIGATOR: Xiang-Dong Fu, PhD CONTRACTING ORGANIZATION:

Clustered mutations of oncogenes and tumor suppressors.

Supplementary Figure 1 Clustered mutations of oncogenes and tumor suppressors. For each oncogene (red dots) and tumor suppressor (blue dots), the number of mutations found in an intramolecular cluster

Disclosure. Relevant Financial Relationship(s) None. Off Label Usage None MFMER slide-1

Disclosure Relevant Financial Relationship(s) None Off Label Usage None 2013 MFMER slide-1 Case Presentation A 43 year old male, with partial nephrectomy for a right kidney mass 2013 MFMER slide-2 2013

Tratamiento neoadyuvante: Enfermedad residual como marcador de resistencia Carlos L. Arteaga, MD Vanderbilt-Ingram Cancer Center Vanderbilt

Tratamiento neoadyuvante: Enfermedad residual como marcador de resistencia Carlos L. Arteaga, MD Vanderbilt-Ingram Cancer Center Vanderbilt University Neoadjuvant (preoperative) therapy Surgery Systemic

Molecular Profiling in Head and Neck Squamous Carcinoma

Molecular Profiling in Head and Neck Squamous Carcinoma Stergios J. Moschos, M.D. Clinical Associate Professor of Medicine University of North Carolina at Chapel Hill Disclosures Paid consultant for Merck,

PI3Kβ Inhibitor TGX221 Selectively Inhibits Renal Cell Carcinoma Cells with Both VHL and SETD2 mutations and Links Multiple Pathways

PI3Kβ Inhibitor TGX221 Selectively Inhibits Renal Cell Carcinoma Cells with Both VHL and SETD2 mutations and Links Multiple Pathways The Harvard community has made this article openly available. Please

FURNARI FRANK SAN DIEGO LUDWIG. Photo by Stewart Marcano

FRANK FURNARI LUDWIG SAN DIEGO Photo by Stewart Marcano 36 THE BRAIN TUMOR DECIPHERER His sustained exploration of the signaling networks, communications and genetic idiosyncrasies of brain cancer cells

State of the Art of Therapeutic Approaches for VHL Disease. VHL Gene and Protein

State of the Art of Therapeutic Approaches for VHL Disease Eric Jonasch, MD UT MD Anderson Cancer Center Houston Texas Coming Up With A Cure: Many Layers of Knowledge are Needed! Identification of the

Interrogating mtor Inhibition in Patients with HRPC

Interrogating mtor Inhibition in Patients with HRPC Daniel George, John Madden, Andrew Armstrong, Mark Dewhirst, Nancy Major, and Phillip Febbo Divisions of Medical Oncology, Urology, Pathology, Radiology,

Epstein-Barr virus driven promoter hypermethylated genes in gastric cancer

RESEARCH FUND FOR THE CONTROL OF INFECTIOUS DISEASES Epstein-Barr virus driven promoter hypermethylated genes in gastric cancer J Yu *, KF To, QY Liang K e y M e s s a g e s 1. Somatostatin receptor 1

SEROUS TUMORS. Dr. Jaime Prat. Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona

SEROUS TUMORS Dr. Jaime Prat Hospital de la Santa Creu i Sant Pau Universitat Autònoma de Barcelona Serous Borderline Tumors (SBTs) Somatic genetics Clonality studies have attempted to dilucidate whether

Non Muscle Invasive Bladder Cancer (NMIBC) Experts Discuss Treatment Options. Part II: The Future Treatment of NMIBC

Non Muscle Invasive Bladder Cancer (NMIBC) Experts Discuss Treatment Options Wednesday, June 14, 2017 Part II: The Future Treatment of NMIBC Presented by Dr. Arlene Siefer-Radtke is an Associate Professor

Lecture 1: Carcinogenesis

Lecture 1: Carcinogenesis Anti-cancer (oncology agents): These are perhaps the most dangerous of drugs, other than the narcotic analgesics. This is due to their toxicities. Killing or inhibiting cancer

Functional genomics reveal that the serine synthesis pathway is essential in breast cancer

Functional genomics reveal that the serine synthesis pathway is essential in breast cancer Results Presented by Stacey Lin Lloyd Lab http://www.amsbio.com/expression-ready-lentiviral-particles.aspx Overview

Clinical Biomarker in Kidney Cancer. Maria Nirvana Formiga, M.D., Ph.D.

Clinical Biomarker in Kidney Cancer Maria Nirvana Formiga, M.D., Ph.D. Disclosures I am on the Speaker s Bureau with Pfizer and Bayer Clinical trials of BMS and Pfizer Kidney Cancer 70% new cases in developed

609G: Concepts of Cancer Genetics and Treatments (3 credits)

Master of Chemical and Life Sciences Program College of Computer, Mathematical, and Natural Sciences 609G: Concepts of Cancer Genetics and Treatments (3 credits) Text books: Principles of Cancer Genetics,

Table S2. Expression of PRMT7 in clinical breast carcinoma samples

Table S2. Expression of PRMT7 in clinical breast carcinoma samples (All data were obtained from cancer microarray database Oncomine.) Analysis type* Analysis Class(number sampels) 1 2 3 4 Correlation (up/down)#

Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis

Li et al. Journal of Experimental & Clinical Cancer Research (218) 37:276 https://doi.org/.1186/s1346-18-924-y RESEARCH Downregulation of CLDN7 due to promoter hypermethylation is associated with human

BIO360 Fall 2013 Quiz 1

BIO360 Fall 2013 Quiz 1 1. Examine the diagram below. There are two homologous copies of chromosome one and the allele of YFG carried on the light gray chromosome has undergone a loss-of-function mutation.

What s New in Pathology of Genitourinary Tumors. Jiaoti Huang, MD, PhD Department of Pathology Duke University School of Medicine

What s New in Pathology of Genitourinary Tumors Jiaoti Huang, MD, PhD Department of Pathology Duke University School of Medicine Kidney Tumors Multilocular cystic renal neoplasm of low malignant potential

FINAL PROGRAM SCHEDULE

51st Annual AAOS Course for Orthopaedic Educators FINAL PROGRAM SCHEDULE November 4 8, 2018 OLC Education & Conference Center Rosemont, IL Robert J. Esther, MD Edmund R. Campion, MD Course Directors PROGRAM

Introduction. Cancer Biology. Tumor-suppressor genes. Proto-oncogenes. DNA stability genes. Mechanisms of carcinogenesis.

Cancer Biology Chapter 18 Eric J. Hall., Amato Giaccia, Radiobiology for the Radiologist Introduction Tissue homeostasis depends on the regulated cell division and self-elimination (programmed cell death)

Type of file: PDF Size of file: 0 KB Title of file for HTML: Supplementary Information Description: Supplementary Figures

Type of file: PDF Size of file: 0 KB Title of file for HTML: Supplementary Information Description: Supplementary Figures Supplementary Figure 1 mir-128-3p is highly expressed in chemoresistant, metastatic

UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY. Giorgio V. Scagliotti University of Torino Dipartment of Oncology

Giorgio V. Scagliotti University of Torino Dipartment of Oncology giorgio.scagliotti@unito.it Molecular landscape of MM not fully characterized to allow personalized treatment Recurrent genetic alterations

Solving Problems of Clustering and Classification of Cancer Diseases Based on DNA Methylation Data 1,2

APPLIED PROBLEMS Solving Problems of Clustering and Classification of Cancer Diseases Based on DNA Methylation Data 1,2 A. N. Polovinkin a, I. B. Krylov a, P. N. Druzhkov a, M. V. Ivanchenko a, I. B. Meyerov

RNA SEQUENCING AND DATA ANALYSIS

RNA SEQUENCING AND DATA ANALYSIS Length of mrna transcripts in the human genome 5,000 5,000 4,000 3,000 2,000 4,000 1,000 0 0 200 400 600 800 3,000 2,000 1,000 0 0 2,000 4,000 6,000 8,000 10,000 Length

New horizons for small cell lung cancers. Charles Rudin MD PhD

New horizons for small cell lung cancers Charles Rudin MD PhD Annual deaths (US) US cancer deaths 140000 120000 100000 80000 60000 40000 20000 0 Cancer type Small cell lung cancer: a disease in need of

Progress in whole genome approaches to

Eur Respir J 2010; 35: 426 443 DOI: 10.1183/09031936.00124709 CopyrightßERS Journals Ltd 2010 SERIES LUNG CANCER Edited by C. Brambilla Number 11 in this Series Progress and applications of mouse models

Cancer. The fundamental defect is. unregulated cell division. Properties of Cancerous Cells. Causes of Cancer. Altered growth and proliferation

Cancer The fundamental defect is unregulated cell division. Properties of Cancerous Cells Altered growth and proliferation Loss of growth factor dependence Loss of contact inhibition Immortalization Alterated

Introduction to Cancer Biology

Introduction to Cancer Biology Robin Hesketh Multiple choice questions (choose the one correct answer from the five choices) Which ONE of the following is a tumour suppressor? a. AKT b. APC c. BCL2 d.

Pathology Mystery and Surprise

Pathology Mystery and Surprise Tim Smith, MD Director Anatomic Pathology Medical University of South Carolina Disclosures No conflicts to declare Some problem cases Kidney tumor Scalp tumor Bladder tumor

Liposarcoma*Genome*Project*

LiposarcomaGenomeProject July2015! Submittedby: JohnMullen,MD EdwinChoy,MD,PhD GregoryCote,MD,PhD G.PeturNielsen,MD BradBernstein,MD,PhD Liposarcoma Background Liposarcoma is the most common soft tissue